Efficacy of Pola-based Treatment in Treatment-Naive Diffuse Large B-Cell Lymphoma: A Real-World Analysis
1. Abstract Polatuzumab vedotin (Pola) has been approved in China as the first-line treatment in Diffuse Large B-Cell Lymphoma (DLBCL). This study aims to evaluate the efficacy of Pola-based therapy in DLBCL in the real-world, offering insights into treatment patterns and outcomes for newly diagnosed DLBCL in this population.
